Predictive biomarkers and molecular subtypes in DLBCL: insights from PCD gene expression and machine learning
This study identifies two distinct DLBCL subtypes based on PCD-related gene expression, with the C2 subtype characterized as high-risk due to enhanced DNA repair and cell cycle pathways. Five key biomarkers (CTSB, DPYD, SCARB2, STOM, GBP1) may improve risk stratification and understanding of DLBCL heterogeneity. These findings lay the groundwork for further exploration of DLBCL progression and potential prognostic improvements.
Authors
- Tiantian He (ORCID: https://orcid.org/0000-0003-4839-681X)
- P. F. He (ORCID: https://orcid.org/0000-0002-3742-6983)
- Jie Geng (ORCID: https://orcid.org/0000-0001-8722-2228)
- Xuechun Lu
- Peng Zhao (ORCID: https://orcid.org/0000-0002-8521-3894)
- Hongyi Li (ORCID: https://orcid.org/0000-0003-2609-5805)
- Hong Zhang (ORCID: https://orcid.org/0000-0002-6039-0640)
- Chuandong Hou (ORCID: https://orcid.org/0009-0002-3188-7639)
Institutions
- Shanxi Medical University (CN)
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1007/s12672-025-02349-x
- Citations
- 6
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 4.84
Funders
- National Natural Science Foundation of China